Clinical Psychiatry News - Low remission seen with third antidepressant: STAR*D trial calls into question the practice of switching classes when an SSRI doesn’t help.(selective serotonin…
Less than 20% of patients switched to a third consecutive antidepressant for major depressive disorder achieved remission in a study published by the STAR*D trial investigators.
They reported low remission rates for mirtazapine and nortriptyline, the two medications compared in the third phase of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (Am. J. Psychiatry 2006;163:1161-72).
Related Results
Post-herpetic neuralgia: a review of advances in treatment and prevention
Antidepressants and smoking Cessation
Low remission seen with third antidepressant: STAR*D trial calls into questio…
ECT patients taking an antidepressant appear to fare well.(electroconvulsive …
CLOBETASOL.(Taro Pharmaceuticals USA receives FDA approval)(Brief Article)
Only 12.3% of 114 patients who switched to mirtazapine reached the trial’s definition of remission: a score of 7 or less on the 17-item Hamilton Rating Scale for Depression …
Read the rest of this article with a Free Trial at HighBeam Research.
